Gabapentin Capsule
Product Images NDC 82868-074

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 82868-074). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Northwind Health Company, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label (82868 074 30 Rev A 04 25 Nhc)

Label for Gabapentin Capsules, USP 100 mg by Northwind Health Company, LLC. The label states 30 capsules per container, prescription only, with storage instructions and packaging information including NDC 82868-074-30.*

FDA Label Image

Equation (Equation)

A mathematical formula illustrating the calculation of creatinine clearance (CLCr), involving factors such as age in years, weight in kilograms, serum creatinine levels in mg/dL, and a correction factor of 0.85 for female patients.*

FDA Label Image

Fig 1 (Fig 1)

Line graph titled 'Weekly Mean Pain Scores' from a clinical study comparing placebo and gabapentin (3600 mg/day) over 8 weeks. The x-axis shows weeks, and the y-axis shows mean pain scores. Gabapentin demonstrates a decreasing trend in pain scores over time compared to placebo.*

FDA Label Image

Fig 2 (Fig 2)

A line graph titled 'Weekly Mean Pain Scores (Observed Cases in ITT Population): Study 2' showing mean pain scores over an 8-week period. The x-axis represents weeks from baseline to week 7, and the y-axis shows mean pain scores ranging from 0 to 10. The graph compares placebo, gabapentin 1800 mg/day, and gabapentin 2400 mg/day groups during a 4-week dose titration period and a 4-week fixed dose period.*

FDA Label Image

Fig 3 (Fig 3)

A bar chart titled 'Proportion of Responders (patients with ≥50% reduction in pain score) at Endpoint: Controlled PHN Studies.' It compares the percentage of responders between placebo (PBO) and gabapentin (GBP) at different doses across two studies, showing higher response rates for gabapentin groups.*

FDA Label Image

Fig 4 (Fig 4)

A scatter plot showing responder rate differences (%) from placebo in patients receiving gabapentin, by daily dose in mg. Data points represent three studies labeled as 'STUDY a,' 'STUDY b,' and 'STUDY c' with differences plotted against doses ranging from 600 to 1800 mg.*

FDA Label Image

Structure (Struct)

Chemical structure diagram showing the molecular structure of gabapentin, including a cyclohexane ring and attached amino and carboxyl groups.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.